Orphagen Partner, Japan Tobacco, Initiates Clinical Trial of Novel Small Molecule Therapeutic for Autoimmune and Allergic Diseases
Read more



Innovative Drugs for Chronic Disease


ROR-gamma Retinitis Pigmentosa Endometriosis orphagen pharma

Orphagen addresses the pharmaceutical industry's need for new classes of drugs that have novel therapeutic mechanisms. We recognize that patients need genuinely new therapies rather than incremental improvements over existing ones.

Our strength is our ability to identify drug-like small molecules that regulate novel drug targets, so-called orphan receptors that are not yet part of mainstream pharmaceutical drug discovery. Our name, “Orphagen”, is based on this expertise. We became an industry leader for our first therapeutic target, in autoimmune disease, and formed a long-term strategic partnership for this target in 2008 with Japan Tobacco. We have active internal drug discovery programs in several other therapeutic areas and look for both investors and partners to advance these programs.

Mission - Research Partner with Orphagen small molecule drug discovery

Orphagen Pharmaceuticals
11558 Sorrento Valley Road, Suite 4
San Diego, CA 92121
Phone: (858) 481-6191